Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Human CD30/TNFRSF8 Protein

Human CD30/TNFRSF8 Protein

CAT#: CAR-T006

Inquiry

Overview Specification

Species	Human
Tag	C-His-Avi
Expression Systems	Expi293
Keywords	Human; C-His-Avi; Expi293

Synonyms	CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1
Background	The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL), and subsets of Non-Hodgkin's lymphomas (NHLs).
Source	Recombinant Human CD30/TNFRSF8 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Phe19-Lys379.
Molecular Weight	The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 68-95 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	>95% as determined by Tris-Bis PAGE. >95% as determined by HPLC.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80℃ for 12 months as supplied from the date of receipt. -20 to -80℃ for 3-6 months in an unopened state after reconstitution. 2-8℃ for 2-7 days after reconstitution.
Notes	Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Online Inquiry

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.